Advances in the diagnosis and treatment of neuroblastoma

Current Opinion in Oncology

Volumn 10, Issue 1, 1998, Pages 43-51

  Katzenstein, Howard M ^a   Cohn, Susan L ^a  

^a CHILDREN'S MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HERMES ANTIGEN; TUMOR MARKER;

ANGIOGENESIS; BONE MARROW TRANSPLANTATION; CANCER CLASSIFICATION; CANCER GENETICS; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CHILDHOOD CANCER; CHROMOSOME DELETION; HETEROZYGOSITY LOSS; HUMAN; INFANT; METASTASIS; MULTIDRUG RESISTANCE; NEURAL CREST CELL; NEUROBLASTOMA; PLOIDY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUMOR GROWTH;

EID: 0031984981     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199801000-00008     Document Type: Review

References (97)

1. Young JL Jr, Miller RW: Incidence of malignant tumors in US children. J Pediatr 1975, 86:254-258.
2. Bowman LC, Castleberry RP, Cantor A, Joshi V, Cohn SL, Smith EI, Yu A, Brodeur GM, Hayes FA, Look AT: Genetic staging of unresectable or metastatic neuroblastoma in infants: a Pediatric Oncology Group study. J Natl Cancer Inst 1997, 89:373-380.
3. Look AT, Hayes FA, Shuster JJ, Douglass EC, Castleberry RP, Bowman LC, Smith EI, Brodeur GM: Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 1991, 9:581-591.
4. Bowman LC, Hancock ML, Santana VM, Hayes FA, Kun L, Parham DM, Furman WL, Rao BN, Green AA, Grist WM: Impact of intensified therapy on clinical outcome in infants and children with neuroblastoma: the St. Jude Children's Research Hospital experience, 1962 to 1988. J Clin Oncol 1991, 9:1599-1608.
5. Evans AE, Gerson J, Schnaufer L: Spontaneous regression of neuroblastoma. Natl Cancer Inst Monogr 1976, 44:49-54.
6. D'Angio GJ, Evans AE, Koop CE: Special pattern of widespread neuroblastoma with a favourable prognosis. Lancet 1971, 1:1046-1049.
7. Haas D, Ablin AR, Miller C, Zoger S, Matthay KK: Complete pathologic maturation and regression of stage IVS neuroblastoma without treatment. Cancer 1988, 62:818-825.
8. Ambras IM, Zellner A, Roald B, Amann G, Ladenstein R, Printz D, Gadner H, Ambros PF: Role of ploidy, chromosome 1p, and Schwann cells in the maturation of neuroblastoma. N Engl J Med 1996, 334:1505-1511.
9. Evans AE, D'Angio GJ, Propert K, Anderson J, Hann HL: Prognostic factors in neuroblastoma. Cancer 1987, 59:1853-1859.
10. Breslow N, McCann B: Statistical estimation of prognosis for children with neuroblastoma. Cancer Res 1971, 31:2098-2103.
11. Evans AE, D'Angio GJ, Randolph J: A proposed staging for children with neuroblastoma. Children's Cancer Study Group A. Cancer 1971, 27:374-378.
12. Nitschke R, Smith EI, Shochat S, Altshuler G, Travers H, Shuster JJ, Hayes FA, Patterson R, McWilliams N: Localized neuroblastoma treated by surgery: a Pediatric Oncology Group study. J Clin Oncol 1988, 6:1271-1279.
13. American Joint Committee on Cancer: Neuroblastoma. In Manual for Staging of Cancer, edn 2. Philadelphia: J.B. Lippincott; 1983:237.
14. Brodeur GM, Seeger RC, Barrert A, Berthold F, Castleberry RP, D'Angio G, De Bernardi B, Evans AE, Favrot M, Freeman AI, et al.: International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol 1988, 6:1874-1881.
15. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castle V, Castelberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F, et al.: Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993, 11:1466-1477.
16. Castleberry RP, Shuster JJ, Smith EI, Member Institutions of the Pediatric Oncology Group: The Pediatric Oncology Group experience with the International Staging System criteria for neuroblastoma. J Clin Oncol 1994, 12:2378-2381.
17. Haase GM, Atkinson JB, Stram DO, Lukens JN, Matthay KK: Surgical management and outcome of locoregional neuroblastoma: comparison of the Childrens Cancer Group and the international staging systems. J Pediatr Surg 1995, 30:289-294.
18. Hann HW, Levy HM, Evans AE: Serum ferritin as a guide to therapy in neuroblastoma. Cancer Res 1980, 40:1411-1413.
19. Quinn JJ, Altman AJ, Frantz CN: Serum lactic dehydrogenase, an indicator of tumor activity in neuroblastoma. J Pediatr 1980, 97:89-91.
20. Zeltzer PM, Marangos PJ, Sather H, Evans A, Siegel S, Wong KY, Dalton A, Seeger R, Hammond D: Prognostic importance of serum neuron specific enolase in local and widespread neuroblastoma. Prog Clin Biol Res 1985, 175:319-329.
21. Zeltzer PM, Marangos PJ, Parma AM, Sather H, Dalton A, Hammond D, Siegel SE, Seeger RC: Raised neuron-specific enolase in serum of children with metastatic neuroblastoma. A report from the Children's Cancer Study Group. Lancet 1983, 2:361-363.
22. Shimada H, Chatten J, Newton WA Jr, Sachs N, Hamoudi AB, Chiba T, Marsden HB, Misugi K: Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 1984, 73:405-416.
23. Joshi VV, Cantor AB, Altshuler G, Larkin EW, Neill JS, Shuster JJ, Holbrook CT, Hayes FA, Nitschke R, Duncan MH, et al.: Age-linked prognostic categorization based on a new histologic grading system of neuroblastomas. A clinicopathologic study of 211 cases from the Pediatric Oncology Group. Cancer 1992, 69:2197-2211.
24. Shimada H, Stram DO, Chatten J, Joshi VV, Hachitanda Y, Brodeur GM, Lukens JN, Matthay KK, Seeger RC: Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis. J Natl Cancer Inst 1995, 87:1470-1476.
25. Cohn SL, Rademaker AW, Salwen HR, Franklin WA, Gonzales-Crussi F, Rosen ST, Bauer KD: Analysis of DNA ploidy and proliferate activity in relation to histology and N-myc amplification in neuroblastoma. Am J Pathol 1990, 136:1043-1052.
26. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM: Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984, 224:1121-1124.
27. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, Hammond D: Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985, 313:1111-1116.
28. Schweigerer L, Breit S, Wenzel A, Tsunamoto K, Ludwig R, Schwab M: Augmented MYCN expression advances the malignant phenotype of human neuroblastoma cells: evidence for induction of autocrine growth factor activity. Cancer Res 1990, 50:4411-4416.
29. Bernards R, Dessain SK, Weinberg RA: N-myc amplification causes down-modulation of MHC class I antigen expression in neuroblastoma. Cell 1986, 47:667-674.
30. Schmidt ML, Salwen HR, Manohar CF, Ikegaki N, Cohn SL: The biologic effects of antisense N-myc expression in human neuroblastoma. Cell Growth Differ 1994, 5:171-178.
31. Negroni A, Scarpa S, Romeo A, Ferrari S, Modesti A, Raschella G: Decrease of proliferation rate and induction of differentiation by a MYCN antisense DNA oligomer in a human neuroblastoma cell line. Cell Growth Differ 1991, 2:511-518.
32. Whitesell L, Rosolen A, Neckers LM: Episome-generated N-myc antisense RNA restricts the differentiation potential of primitive neuroectodermal cell lines. Mol Cell Biol 1991, 11:1360-1371.
33. Chagnovich D, Cohn SL: Binding of a 40-kDa protein to the N-myc 3′ untranslated region correlates with enhanced N-myc expression in human neuroblastoma. J Biol Chem 1996, 271:33580-33586.
34. Chagnovich D, Fayos BE, Cohn SL: Differential activity of ELAV-like RNA-binding proteins in human neuroblastoma. J Biol Chem 1996, 271:33587-33591.
35. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM: Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 1997, 16:2985-2995.
36. Cohn SL, Look AT, Joshi VV, Holbrook T, Salwen H, Chagnovich D, Chester L, Rowe ST, Valentine MB, Komuro H, et al.: Lack of correlation of N-myc gene amplification with prognosis in localized neuroblastoma: a Pediatric Oncology Group study. Cancer Res 1995, 55:721-726.
37. Fabbretti G, Valenti C, Loda M, Brisigotti M, Cozzutto C, Paolo T, Callea F: N-myc gene amplification/expression in localized stroma-rich neuroblastoma (ganglioneuroblastoma). Hum Pathol 1993, 24:294-297.
38. Rubie H, Hartmann O, Michon J, Frappaz D, Coze C, Chastagner P, Baranzelli MC, Plantaz D, Avet-Loiseau H, Benard J, et al.: N-myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 Study. J Clin Oncol 1997, 15:1171-1182.
39. Tonini GP, Boni L, Pession A, Rogers D, Iolascon A, Basso G, Cordero di Montezemolo L, Casale F, Perri P, Mazzocco K, et al.: MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: The Italian Experience with 295 children. J Clin Oncol 1997, 15:85-93.
40. Look AT, Hayes FA, Nitschke R, McWilliams NB, Green AA: Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med 1984, 311:231-235.
41. Taylor SR, Locker J: A comparative analysis of nuclear DNA content and N-myc gene amplification in neuroblastoma. Cancer 1990, 65:1360-1366.
42. Bourhis J, DeVathaire F, Wilson GD, Hartmann O, Terrier-Lacombe MJ, Boccon-Gibod L, McNally NJ, Lemerie J, Riou G, Benard J: Combined analysis of DNA ploidy index and N-myc genomic content in neuroblastoma. Cancer Res 1991, 51:33-36.
43. Brodeur GM, Fong CT: Molecular biology and genetics of human neuroblastoma. Cancer Genet Cytogenef 1989, 41:153-174.
44. Brodeur GM, Green AA, Hayes FA, Williams KJ, Williams DL, Tsiatis AA: Cytogenetic features of human neuroblastomas and cell lines. Cancer Res 1981, 41:4678-4686.
45. Laureys G, Speleman F, Opdenakker G, Benoit Y, Leroy J: Constitutional translocation t(1;17)(p36;q12-21) in a patient with neuroblastoma. Genes Chromosom Cancer 1990, 2:252-254.
46. Biegel JA, White PS, Marshall HN, Fujimori M, Zackai EH, Scher CD, Brodeur GM, Emanuel BS: Constitutional 1p36 deletion in a child with neuroblastoma. Am J Hum Genet 1993, 52:176-182.
47. Maris JM, Kyemba SM, Rebbeck TR, White PS, Sulman EP, Jensen SJ. Allen C, Biegel JA, Yanofsky RA, et al.: Familial predisposition to neuroblastoma does not map to chromosome band 1p36. Cancer Res 1996, 56:3421-3425.
48. Fong CT, Dracopoli NC, White PS, Merrill PT, Griffith RC, Housman DE, Brodeur GM: Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: correlation with N-myc amplification. Proc Natl Acad Sci U S A 1989, 86:3753-3757.
49. Maris JM, White PS, Beltinger CP, Sulman EP, Castleberry RP, Shuster JJ, Look AT, Brodeur GM: Significance of chromosome 1p loss of heterozygosity In neuroblastoma. Cancer Res 1995, 55:4664-4669.
50. Gehring M, Berthold F, Edler L, Schwab M, Amler LC: The 1p deletion is not a reliable marker for the prognosis of patients with neuroblastoma. Cancer Res 1995, 55:5366-5369.
51. Caron H, van Sluis P, de Kraker J, Bokkerink J, Egeler M, Laureys G, Slater R, Westerveld A, Voute PA, Versteeg R: Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med 1996, 334:225-230.
52. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, Azar CG, Cantor AB, Brodeur GM: Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 1993, 328:847-854.
53. Kogner P, Barbany G, Dominici C, Castello MA, Raschella G, Persson H: Coexpression of messenger RNA for TRK protooncogene and low affinity nerve growth factor receptor in neuroblastoma with favorable prognosis. Cancer Res 1993, 53:2044-2050.
54. Borrello MG, Bongarzone I, Pierotti MA, Luksch R, Gasparini M, Collini P, Pilotti S, Rizzetti MG, Mondellini P, DeBernardi B, et al.: TRK and RET protooncogene expression in human neuroblastoma specimens: High-frequency of TRK expression In non-advanced stages. Int J Cancer 1993, 54:540-545.
55. Suzuki T, Bogenmann E, Shimada H, Stram D, Seeger RC: Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas. J Natl Cancer Inst 1993, 85:337-384.
56. Brodeur GM, Nakagawara A, Yamashiro DJ, Ikegaki N, Liu XG, Azar CG, Lee CP, Evans AE: Expression of TrkA, TrkB and TrkC in human neuroblastomas. J Neurooncol 1997, 31:49-55.
57. Ryden M, Sehgal R, Dominici C, Schilling FH, Ibanez CF, Kogner P: Expression of mRNA for the neurotrophin receptor trkC in neuroblastomas with favourable tumour stage and good prognosis. Br J Cancer 1996, 74:773-779.
58. Yamashiro DJ, Nakagawara A, Ikegaki N, Liu XG, Brodeur GM: Expression of TrkC in favorable human neuroblastomas. Oncogene 1996, 12:37-41.
59. Nakagawara A, Azar CG, Scavarda NJ, Brodeur GM: Expression and function of TRK-B and BDNF in human neuroblastomas. Mol Cell Biol 1994, 14:759-767.
60. Bordow SB, Haber M, Madafiglio J, Cheung B, Marshall GM, Norris MD: Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene in childhood neuroblastoma. Cancer Res 1994, 54:5036-5040.
61. Norris MD, Bordow SB, Marshall GM, Haber PS, Cohn SL, Haber M: Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med 1996, 334:231-238.
62. Chan HSL, Haddad G, Thorner PS, DeBoer G, Lin YP, Ondrusek N, Yeger H, Ling V: P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 1991, 325:1608-1614.
63. Favrot M, Combaret V, Goillot E, Wagner JP, Bouffet E, Mazingue F, Thyss A, Bordigoni P, Delsol G, Bailly C: Expression of P-glycoprotein restricted to normal cells in neuroblastoma biopsies. Br J Cancer 1991, 64:233-238.
64. Nakagawara A, Kadomatsu K, Sato S, Kohno K, Takano H, Akazawa K, Nose Y, Kuwano M: Inverse correlation between expression of multidrug resistance gene and N-myc oncogene in human neuroblastomas. Cancer Res 1990, 50:3043-3047.
65. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G: Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992, 84:1875-1887.
66. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990, 82:4-6.
67. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993, 143:401-409.
68. Meitar D, Crawford SE, Rademaker AW, Cohn SL: Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J Clin Oncol 1996, 14:405-414.
69. Wassberg E, Pahlman S, Westlin JE, Christofferson R: The angiogenesis inhibitor TNP-470 reduces the growth rate of human neuroblastoma in nude rats. Pediatr Res 1997, 41:327-333.
70. Nagabuchi E, VanderKolk WE, Une Y, Ziegler MM: TNP-470 antiangiogenic therapy for advanced murine neuroblastoma. J Pediatr Surg 1997, 32:287-293.
71. Combaret V, Gross N, Lasset C, Frappaz D, Peruisseau G, Philip T, Beck D, Favrot MC: Clinical relevance of CD44 cell-surface expression and N-myc gene amplification in a multicentric analysis of 121 pediatric neuroblastomas. J Clin Oncol 1996, 14:25-34.
72. Combaret V, Lasset C, Frappaz D, Bouvier R, Thiesse P, Rebillard AC, Philip T, Favrot MC: Evaluation of CD44 prognostic value in neuroblastoma: comparison with the other prognostic factors. Eur J Cancer 1995, 31A:545-549.
73. Gross N, Balmas K, Brognara CB: Absence of functional CD44 hyaluronan receptor on human NMYC-amplifled neuroblastoma cells. Cancer Res 1997, 57:1387-1393.
74. Comito MA, Savell VH, Cohen MB: CD44 expression In neuroblastoma and related tumors. J Pediatr Hematol Oncol 1997, 19:292-296.
75. Matthay KK, Sather HN, Seeger RC, Haase GM, Hammond GD: Excellent outcome of stage II neuroblastoma is independent of residual disease and radiation therapy. J Clin Oncol 1989, 7:236-244.
76. Kushner BH, Cheung NV, LaQuaglia MP, Ambros PF, Bonilla MA, Ladanyi M, Gerald WL: International neuroblastoma staging system stage 1 neuroblastoma: a prospective study and literature review. J Clin Oncol 1996, 14:2174-2180.
77. Evans AE, Silber JH, Shpilsky A, D'Angio GJ: Successful management of low-stage neuroblastoma without adjuvant therapies: a comparison of two decades, 1972 through 1981 and 1982 through 1992, in a single institution. J Clin Oncol 1996, 14:2504-2510.
78. West DC, Shamberger RC, Macklis RM, Kozakewich HP, Wayne AS, Kreissman SG, Korf BR, Lavally B, Grier HE: Stage III neuroblastoma over 1 year of age at diagnosis: Improved survival with intensive multimodality therapy including multiple alkylating agents. J Clin Oncol 1993, 11:84-90.
79. Philip T, Zucker JM, Bernard JL, Lutz P, Bordigoni P, Plouvier E, Robert A, Roche H, Souillet G, Bouffet E, et al.: Improved survival at 2 and 5 years in the LMCE1 unselected group of 72 children with stage IV neuroblastoma older than 1 year of age at diagnosis: is cure possible in a small subgroup? J Clin Oncol 1991, 9:1037-1044.
80. Cheung NK, Heller G: Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma. J Clin Oncol 1991, 9:1050-1058.
81. Seeger RC, Matthay KK, Villablanca JG, Harris R, Feig SA, Selch M, Stram D, Reynolds CP: Intensive chemoradiotherapy and autologous bone marrow transplantation (ABMT) for high risk neuroblastoma. Proc Am Soc Clin Oncol 1991, 10:310.
82. Pole JG, Casper J, Elfenbein G, Gee A, Gross S, Janssen W, Koch P, Marcus R, Pick T, Shuster J, et al.: High-dose chemoradiotherapy supported by marrow infusions for advanced neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 1991, 9:152-158.
83. Stram DO, Matthay KK, O'Leary M, Reynolds CP, Haase GM, Atkinson JB, Brodeur GM, Seeger RC: Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group studies. J Clin Oncol 1996, 14:2417-2426.
84. McCowage GB, Vowels MR, Shaw PJ, Lockwood L, Mameghan H: Autologous bone marrow transplantation for advanced neuroblastoma using teniposide, doxorubicin, melphalan, cisplatin, and total-body irradiation. J Clin Oncol 1995, 13:2789-2795.
85. Saarinen UM, Wikstrom S, Makipernaa A, Lanning M, Perkkio M, Hovi L, Rapola J, Sariola H: In vivo purging of bone marrow in children with poor-risk neuroblastoma for marrow collection and autologous bone marrow transplantation. J Clin Oncol 1996, 14:2791-2802.
86. Cohn SL, Moss TJ, Hoover M, Katzenstein HM, Haut PH, Morgan ER, Green AA, Kletzel M: Treatment of poor-risk neuroblastoma patients with high-dose chemotherapy and autologous peripheral stem cell rescue. Bone Marrow Transplant 1997, 20:543-551.
87. Di Caro A, Bostrom B, Moss TJ, Neglia J, Ramsay NK, Smith J, Sasky LC: Autologous peripheral blood cell transplantation in the treatment of advanced neuroblastoma. Am J Pediatr Hematol Oncol 1994, 16:200-206.
88. Mitchell PL, Shepherd VB, Proctor HM, Dainton M, Cabral SD, Pinkerton CR: Peripheral blood stem cells used to augment autologous bone marrow transplantation. Arch Dis Child 1994, 70:237-240.
89. Miyajima Y, Horibe K, Fukuda M, Matsumoto K, Numata S, Mori H, Kato K: Sequential detection of tumor cells in the peripheral blood and bone marrow of patients with stage IV neuroblastoma by the reverse transcription-polymerase chain reaction for tyrosine hydoxylase mRNA. Cancer 1996, 77:1214-1219.
90. de Kraker J, Hoefnagel CA, Caron H, Valdes Olmos RA, Zsiros J, Heij HA, Voute PA: First line targeted radiotherapy, a new concept in the treatment of advanced stage neuroblastoma. Eur J Cancer 1995, 31A:600-602.
91. Lashford LS, Lewis IJ, Fielding SL, Flower MA, Meller S, Kemshead JT, Ackery D: Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children's Cancer Study Group investigation. J Clin Oncol 1992, 10:1889-1896.
92. Voute PA, van der Kleij AJ, de Kraker J, Hoefnagel CA, Tiel-van Buul MM, Van Gennip H: Clinical experience with radiation enhancement by hyperbaric oxygen in children with recurrent neuroblastoma stage IV. Eur J Cancer 1995, 31A:596-600.
93. Cheung NK, Lazarus H, Miraldi FD, Abramowsky CR, Kallick S, Saarinen UM, Spitzer T, Strandjord SE, Coccia PF, Berger NA: Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 1987, 5:1430-1440.
94. Murray JL, Cunningham JE, Brewer H, Mujoo K, Zukiwski AA, Podoloff DA, Kasi LP, Bhadkamkar V, Fritsche HA, Benjamin RS: Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol 1994, 12:184-193.
95. Villablanca JG, Khan AA, Avramis VI, Seeger RC, Matthay KK, Ramsay NK, Reynolds CP: Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation. J Clin Oncol 1995, 13:894-901.
96. Michon J, Negrier S, Coze C, Mathiot C, Frappaz D, Oskam R, Pacquement H, Quintana E, Bouffet E, Bernard JL, et al.: Administration of high-dose recombinant interleukin 2 after autologous bone marrow transplantation In patients with neuroblastoma: toxicity, efficacy and survival. A Lyon-Marseille-Curie-East of France Group Study. Prog Clin Biol Res 1994, 385:293-300.
97. Bauer M, Reaman GH, Hank JA, Cairo MS, Anderson P, Blazar BR, Frierdich S, Sondel PM: A phase II trial of human recombinant interleukin-2 administered as a 4-day continuous infusion for children with refractory neuroblastoma, non-Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A Childrens Cancer Group study. Cancer 1995, 75:2959-2965.